Deterra Icon Graphic

At-Home Drug Disposal Funding Sources

Grants and Opioid Settlements can help fund prevention efforts

Grants and opioid settlements can provide critical funding for prevention efforts, but understanding how to secure these funds can be an intimidating process.

Below, you’ll find links to funding sources that other organizations have had success in using to purchase and distribute evidence-based prevention solutions like the Deterra® Drug Deactivation and Disposal System.

Deterra Grant Guide

To help you navigate the world of grant opportunities, we’ve put together a free guide with practical tips on how to secure funds for proven tools like Deterra.

This guide is a great starting point for private, nonprofit and government organizations that want to include Deterra as part of a larger prevention program or fund a stand-alone drug deactivation and disposal campaign.

In this guide, you’ll find:

  • Examples and evidence to support your grant application, including commonly required information as well as sample language
  • Links to potential sources of public and private funding
  • Case studies that show how other organizations like yours have used grants to support the distribution of Deterra


Deterra Grant Guide
A hand writing on a legal pad

Get Expert Tips on Grant Writing

Fill out the form below to see best practices for writing a strong grant application.

  • Fields marked with * are required.

  • (optional)
  • This field is for validation purposes and should be left unchanged.

Funding Sources for At-Home Drug Deactivation Solutions

Prevention resources like Deterra are an eligible expense for many grant opportunitiesBelow are funding sources that organizations have used successfully and that could be good options for you.

Additional funding is released throughout the year, so it’s a good idea to be on the lookout for funding announcements. Application criteria, deadlines and requirements are frequently updated, so check with your local authorities about available grants in your jurisdiction.


Indigenous Communities & Tribal Governments

  • Tribal Opioid Response (TOR) Grants
    The Substance Abuse and Mental Health Services Administration (SAMHSA) is requesting $50 million in fiscal year 2022 for the SAMHSA Tribal Opioid Response Grants. These grants aim to address the opioid crisis in tribal communities by increasing access to culturally appropriate and evidence-based treatment, prevention, and outreach.


  • Opioid Litigation Funds  
    Funds from opioid litigation settlements, like the $75 million recently awarded to Cherokee Nation by three top drug distributors, can enable investments in behavioral health and recovery resources to help tribal members impacted by the opioid crisis.  


Rural Communities

  • Rural Communities Opioid Response Program (RCORP) Grants
    RCORP is a multi-year initiative that addresses barriers to treatment for substance use disorder (SUD), including opioid use disorder (OUD). This program is open to all domestic public or private, non-profit or for-profit entities, including federally recognized tribes as well as faith-based and community-based groups.


State and Local Governments

  •  State Opioid Response (SOR) Grants   
    The Substance Abuse and Mental Health Services Administration (SAMHSA) is anticipating $1.4 billion in fiscal year 2022 for the SAMHSA State Opioid Response Grants. These grants are awarded to provide states, tribes, and U.S. territories with flexibility to address the specific substance use-related issues in an area. 


  • American Rescue Plan Fiscal Recovery Funds
    The American Rescue Plan will deliver $350 billion for eligible state, local, territorial and tribal governments to respond to the Covid-19 emergency. Funds can address systemic public health and economic challenges that have contributed to the unequal impact of the pandemic. This includes:   
      • Areas that have been negatively impacted by COVID-19 which include drug overdoses. 
      • Mental health treatment, substance misuse treatment, other behavioral health services, hotlines or warmlines, crisis intervention, overdose prevention.


  • Opioid Settlement Funds
    $26 billion from multidistrict litigation (MDL) settlement funds will be allocated to all 50 states at the state and county levels. In addition to the MDL funds, there are two other settlements that impact multiple states:  

    • McKinsey Legislation: $529 million will be allocated to 45 states and distributed by state Attorneys General based on the abatement plan.  
    • Purdue Pharma Legislation: $2 billion will be distributed to 15 states and allocated by the state Attorney General based on the settlement’s abatement plan.  


Law Enforcement

  • BJA COSSAP Grants
    For 2022, the Office of Justice Programs (OJP) requests $631.9 million to support a range of programs including the Comprehensive Opioid, Stimulant, and Substance Abuse Program; Drug Courts; Veterans Treatment Courts; programs for youth; and the Residential Substance Abuse Treatment Program. OJP grants provide flexibility to state, local, and tribal jurisdictions to address substance use under all its drug-related programs depending on local needs.


  • BJA Comprehensive Secure & Responsible Drug Disposal Program
    The Bureau of Justice Assistance (BJA) Comprehensive Secure and Responsible Drug Disposal Program supports state, local and tribal drug disposal and take-back efforts. Grantees will be awarded up to $100,000 each to purchase drug take-back/storage and disposal equipment, including drop boxes and disposal pouches. State agencies and departments, units of local government or local agencies, and federally recognized Indian tribal entities are eligible to apply.


Questions? Contact us

Contact us to learn more about funding options to make at-home drug disposal part of your prevention efforts.

Ending the opioid crisis requires a collective effort to get evidence-based prevention methods into the hands of those who need them most. Increasing access to at-home drug deactivation and disposal resources is key to preventing unused medications from becoming sources of misuse or environmental harm.”